Mojave Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
To improve antigen recognition, Mojave Therapeutics is harnessing the intracellular antigenic peptide chaperone function of heat shock proteins. It has created a universal cassette for antigen delivery using hsp's, which it calls Javelin technology, that is applicable for active immunotherapy of infectious diseases and cancer.
You may also be interested in...
Can Heat Shock Proteins Improve Immunotherapy?
Therapeutic vaccines derived from antigenic peptides have yet to demonstrate significant efficacy, particularly in cancer. Over the past eight years, a series of observations has led a small group of companies to believe that heat shock proteins possess unique properties that could make them useful adjuvants in vaccines designed to generate specific immune responses against cancers and infectious agents.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.